Glenmark Pharmaceuticals Limited has approved the transfer of its Nebulizer brands and intellectual property portfolio to Glenmark Healthcare Limited, a wholly owned subsidiary. The board approved the transfer at its meeting held on May 29, 2026.
The transfer will be carried out at a cash consideration of Rs 223 crore, based on an independent valuer report. The sale agreement is scheduled to be entered into on June 1, 2026, and the transaction is expected to be completed on or before June 30, 2026. No change in the shareholding pattern of Glenmark Pharmaceuticals will result from this transfer.
For the nine months ended December 31, 2025, the Nebulizer business recorded revenue of Rs 71.6 crore, representing approximately 1.3% of Glenmark Pharmaceuticals' standalone revenue for the corresponding period. The net worth of the GHL business as on March 31, 2026, stood at negative Rs 9.9 crore. The Nebulizer business operates across India and emerging markets.
Glenmark Healthcare is engaged in manufacturing pharmaceutical products. The subsidiary is setting up a new dedicated Nebulizer manufacturing facility. Glenmark Healthcare will also house a portfolio of Nebulizers including a nebulized triple therapy for Chronic Obstructive Pulmonary Disease.
The transaction is with a related party and has been conducted at arm's length. The transfer of the complete Nebulizer brands and IP portfolio to Glenmark Healthcare is expected to allow sharper focus on this business. The subsidiary will manufacture the Nebulizer products at its upcoming facility.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.